ININFA   02677
INSTITUTO DE INVESTIGACIONES FARMACOLOGICAS
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Metabolic syndrome among patients with mental disorders treated with antipsychotics
Autor/es:
HERBST, LUIS; SAIDMAN, NORBERTO; CASSANELLI, MARTÍN; CORTESI, SANTIAGO; GOLDCHLUK, ANÍBAL; LEIDERMAN, E; SILVIA INES WIKINSKI
Lugar:
San Diego
Reunión:
Congreso; 166th Annual Meeting of the American Pshchiatric Association; 2013
Institución organizadora:
American Pshchiatric Association
Resumen:
METABOLIC SYNDROME AMONG PATIENTS WITH CHRONIC METAN DISORDERS TREAETED WITH ANTIPSYCHOTICS.   Herbst LG, Saidman N, Cassanelli M, Leiderman E, goldchluck A, Cortesi S,, Wikinski S.   Introduction: People affected by chronic mental disorders have an increased cardiovascular risk. Antipschotic treatment could contribute to it by inducing metabolic syndrome. The aim of this study is to obtain local data about the prevalence of metabolic syndrome in patients with chronic mental disorders treated with antipsychotics in an outpatient unit. The stydy was approved by the Ethics Committees of the Hospital Borda and the School of Pharmacy and biochemistry, University of Buenos Aires. Method: All patients treated with antipsychotics who consulted consecutively in the outpatient unit between July and August 2011 were included. The sample consisted of 123 patients (107 men and 16 women), 86 were diagnosed with schizophrenia, 19 with bipolar disorder and 18 with other diagnoses. Demographic data were obtained and anthropometric and blood pressure measurements were performed. A blood sample was obtained to perform the following biochemical analysis: fasting blood glucose, insulin, total cholesterol, LDL and HDL cholesterol, triblycerides, C-reactive protein and TSH. Results: Using the ATP-III criteria (NCEP) 35.5% of men and 56,2% of women presented metabolic syndrome. Both, the percentage of men and women affected is higher than that observed in the general population in Argentina (estimated at 21 to 28% of men and 14 to 22% of women). Central obesity seems to contribute to this prevalence. Chi square analysis revealed no statistical differences between prevalence of metabolic syndrome in patients receiving typical or atypical antipsychotics, or receiving one or more than one antipsychotic drug. Time elapsed from the beginning of the pharmacological treatment (i.e. less vs more than 15 years) was neither related with the presence of metabolic syndrome. Conclusion: this is the first local work aimed to invesdtigate the prevalence of metabolic syndrome inpatients treated with antipsychotics. Our results show prevalence similar to that reported in CATIE study, and significantly higher than that observed in the general population, according to published data in our country.